FI3452039T3 - Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä - Google Patents
Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä Download PDFInfo
- Publication number
- FI3452039T3 FI3452039T3 FIEP17793380.1T FI17793380T FI3452039T3 FI 3452039 T3 FI3452039 T3 FI 3452039T3 FI 17793380 T FI17793380 T FI 17793380T FI 3452039 T3 FI3452039 T3 FI 3452039T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- used according
- weight
- day
- hair loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331827P | 2016-05-04 | 2016-05-04 | |
| US201662338869P | 2016-05-19 | 2016-05-19 | |
| US201662418774P | 2016-11-07 | 2016-11-07 | |
| US201662419237P | 2016-11-08 | 2016-11-08 | |
| US201662434404P | 2016-12-14 | 2016-12-14 | |
| US201762466358P | 2017-03-02 | 2017-03-02 | |
| US201762492758P | 2017-05-01 | 2017-05-01 | |
| PCT/US2017/031142 WO2017192905A1 (en) | 2016-05-04 | 2017-05-04 | Treatment of hair loss disorders with deuterated jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3452039T3 true FI3452039T3 (fi) | 2024-10-02 |
Family
ID=60203616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17793380.1T FI3452039T3 (fi) | 2016-05-04 | 2017-05-04 | Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10561659B2 (enExample) |
| EP (2) | EP4424367A3 (enExample) |
| JP (3) | JP7145080B2 (enExample) |
| KR (3) | KR20190003711A (enExample) |
| CN (3) | CN122440641A (enExample) |
| AU (3) | AU2017261286B2 (enExample) |
| BR (1) | BR112018072339A2 (enExample) |
| CA (1) | CA3022519A1 (enExample) |
| DK (1) | DK3452039T3 (enExample) |
| ES (1) | ES2988629T3 (enExample) |
| FI (1) | FI3452039T3 (enExample) |
| HR (1) | HRP20241345T1 (enExample) |
| HU (1) | HUE068643T2 (enExample) |
| LT (1) | LT3452039T (enExample) |
| MX (6) | MX388054B (enExample) |
| PL (1) | PL3452039T3 (enExample) |
| PT (1) | PT3452039T (enExample) |
| RS (1) | RS66006B1 (enExample) |
| SI (1) | SI3452039T1 (enExample) |
| SM (1) | SMT202400389T1 (enExample) |
| WO (1) | WO2017192905A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561659B2 (en) * | 2016-05-04 | 2020-02-18 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated JAK inhibitors |
| EP3921318A1 (en) * | 2019-02-06 | 2021-12-15 | Concert Pharmaceuticals Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| WO2021236139A1 (en) * | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| US12643902B2 (en) | 2020-08-12 | 2026-06-02 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched substituted pyrrolo[2,3-d]pyrimidines |
| US20220213105A1 (en) | 2020-08-12 | 2022-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| CN116916927A (zh) * | 2020-10-28 | 2023-10-20 | 太阳医药工业公司 | 用于用氘化jak抑制剂治疗脱发症的方案 |
| US20230390292A1 (en) * | 2020-10-28 | 2023-12-07 | Sun Pharmaceutical Industries, Inc. | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
| CN112402615A (zh) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | 一种用于治疗斑秃的复方外用制剂及其制备方法 |
| WO2023018904A1 (en) | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| AU2022328282A1 (en) | 2021-08-12 | 2024-02-22 | Sun Pharmaceutical Industries, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
| WO2023215520A1 (en) | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
| WO2026020112A1 (en) * | 2024-07-19 | 2026-01-22 | Sun Pharmaceutical Industries, Inc. | Oral formulations of deuruxolitinib |
| US20260027120A1 (en) * | 2024-07-25 | 2026-01-29 | Sun Pharmaceutical Industries, Inc. | Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CZ20033211A3 (cs) | 2001-05-03 | 2004-09-15 | F. Hoffmann-La Roche Ag | Farmaceutická léková forma amorfního nelfinavir mesylátu |
| WO2006039237A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| PT2635299T (pt) * | 2010-11-02 | 2019-10-14 | Univ Columbia | Métodos de tratamento de distúrbios de perda de cabelo |
| DK2830662T3 (da) | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
| EP3450434B1 (en) | 2012-06-15 | 2021-02-24 | CoNCERT Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| CA2879400A1 (en) * | 2012-07-30 | 2014-02-06 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
| KR102242077B1 (ko) * | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CN104725380B (zh) * | 2013-12-18 | 2019-06-28 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| MX2016010213A (es) * | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| US10561659B2 (en) | 2016-05-04 | 2020-02-18 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated JAK inhibitors |
| WO2023018904A1 (en) * | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
-
2017
- 2017-05-04 US US16/098,338 patent/US10561659B2/en active Active
- 2017-05-04 AU AU2017261286A patent/AU2017261286B2/en active Active
- 2017-05-04 WO PCT/US2017/031142 patent/WO2017192905A1/en not_active Ceased
- 2017-05-04 CN CN202610044633.5A patent/CN122440641A/zh active Pending
- 2017-05-04 CN CN202610039132.8A patent/CN121868312A/zh active Pending
- 2017-05-04 CA CA3022519A patent/CA3022519A1/en active Pending
- 2017-05-04 HR HRP20241345TT patent/HRP20241345T1/hr unknown
- 2017-05-04 KR KR1020187034867A patent/KR20190003711A/ko not_active Ceased
- 2017-05-04 MX MX2018013347A patent/MX388054B/es unknown
- 2017-05-04 FI FIEP17793380.1T patent/FI3452039T3/fi active
- 2017-05-04 LT LTEPPCT/US2017/031142T patent/LT3452039T/lt unknown
- 2017-05-04 PL PL17793380.1T patent/PL3452039T3/pl unknown
- 2017-05-04 EP EP24175652.7A patent/EP4424367A3/en active Pending
- 2017-05-04 SI SI201731552T patent/SI3452039T1/sl unknown
- 2017-05-04 ES ES17793380T patent/ES2988629T3/es active Active
- 2017-05-04 DK DK17793380.1T patent/DK3452039T3/da active
- 2017-05-04 KR KR1020257015799A patent/KR20250070139A/ko active Pending
- 2017-05-04 JP JP2018557837A patent/JP7145080B2/ja active Active
- 2017-05-04 EP EP17793380.1A patent/EP3452039B1/en active Active
- 2017-05-04 SM SM20240389T patent/SMT202400389T1/it unknown
- 2017-05-04 RS RS20241081A patent/RS66006B1/sr unknown
- 2017-05-04 KR KR1020237019001A patent/KR102810262B1/ko active Active
- 2017-05-04 PT PT177933801T patent/PT3452039T/pt unknown
- 2017-05-04 BR BR112018072339-8A patent/BR112018072339A2/pt not_active Application Discontinuation
- 2017-05-04 CN CN201780027427.2A patent/CN109069493A/zh active Pending
- 2017-05-04 HU HUE17793380A patent/HUE068643T2/hu unknown
-
2018
- 2018-10-31 MX MX2023002325A patent/MX2023002325A/es unknown
- 2018-10-31 MX MX2023002323A patent/MX2023002323A/es unknown
- 2018-10-31 MX MX2023002321A patent/MX2023002321A/es unknown
- 2018-10-31 MX MX2021014175A patent/MX2021014175A/es unknown
- 2018-10-31 MX MX2023002324A patent/MX2023002324A/es unknown
-
2019
- 2019-12-05 US US16/704,402 patent/US12076323B2/en active Active
-
2022
- 2022-09-16 JP JP2022147751A patent/JP7586868B2/ja active Active
-
2023
- 2023-02-24 AU AU2023201112A patent/AU2023201112B2/en active Active
-
2024
- 2024-06-26 US US18/755,253 patent/US20240423986A1/en active Pending
- 2024-11-07 JP JP2024195175A patent/JP2025026895A/ja active Pending
-
2025
- 2025-08-06 AU AU2025213576A patent/AU2025213576A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241345T1 (hr) | Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| JP2016147915A5 (enExample) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| FI3307271T3 (fi) | Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2019002212A (es) | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| MX2016006564A (es) | Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos. | |
| PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MY182403A (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| PH12015500313A1 (en) | Orally administered medical composition | |
| JP2019516684A5 (enExample) | ||
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| JP2017533265A5 (enExample) | ||
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| NZ745065A (en) | Methods for treatment and prophylaxis of hiv and aids | |
| WO2018089328A8 (en) | TREATMENT OF CNS DISEASES USING GCS STIMULATORS | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom |